DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Otros (Other)
Harnessing homeostatically active RhoC at cell junctions preserves human endothelial barrier function during inflammation
The GTPase RhoA plays a critical role in generating actomyosin-mediated contractile forces that cause endothelial hyperpermeability during systemic inflammatory diseases. RhoA is almost identical to RhoB and RhoC, all of which are molecular targets of specific bacterial toxins. Searching for new treatments to modulate Rho-dependent endothelial integrity, we demonstrate that the selective and simultaneous activation of these three Rho GTPases with a chimeric recombinant toxin does not induce cell contraction but enhances microvascular endothelial barrier function in response to pathological inflammatory challenges in vitro and in vivo. This pro-barrier effect is specifically mediated by RhoC, whose activity is increased by cell confluence. The uniqueness of RhoC relies on an arginine residue (R188) within its hypervariable region that determines its junctional localization, high homeostatic activity, and barrier-protective function, in contrast to the permeability-inducing, low homeostatic activity of RhoA and RhoB. Quantitative proteomics and high-resolution confocal microscopy revealed that RhoC regulates perijunctional actomyosin and the expression of myosin light chain proteins. Thus, harnessing the activity of RhoC represents a potential therapy for strengthening endothelial barriers during pathological inflammation., The expert technical advices of the confocal microscopy, electron microscopy, genomic
and animal facilities are gratefully acknowledged. The work was supported by grants
PID2020-119881RB-I00 from AEI (to CC-N, PM-P, NC-A, SB, GdR, GC-T, and JM)
and Grant TomoXliver2, Ref: S2022/BMD-7232 funded by Comunidad Autónoma de
Madrid. (to SB and JM), and IND2019/BMD-17139 (to GC-T and JM) from
Comunidad de Madrid. This research work was also funded by the European
Commission─NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global
Health Platform (PTI Salud Global) (to JM). SB is also supported by Endocornea2,
Convenio Colaboración CSIC, funded by Instituto de Investigación Fundación Jiménez
Díaz. The authors also thank Dr Phil Mason, who provided English language support., No